Erratum: Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis (Molecular Pharmaceutics (2012) 9:1 (187-195) DOI: 10.1021/mp200461s));Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis

Molecular Pharmaceutics

Volumn 9, Issue 1, 2012, Pages 187-195

  Dixon, Andrew S ^a   Miller, Geoffrey D ^a   Bruno, Benjamin J ^a   Constance, Jonathan E ^a   Woessner, David W ^a   Fidler, Trevor P ^a   Robertson, James C ^b   Cheatham, Thomas E ^c   Lim, Carol S ^a  

^a Department of Pharmaceutics and Pharmaceutical Chemistry ^*  (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Department of Medicinal Chemistry   (United States)

Author keywords

Bcr Abl; chronic myelogenous leukemia (CML); mutant coiled coil; oligomerization disruption

Indexed keywords

BCR ABL PROTEIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; COILED COIL DOMAIN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 84855433160     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300089a     Document Type: Erratum

References (43)

1. McWhirter, J. R.; Galasso, D. L.; Wang, J. Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins Mol. Cell. Biol. 1993, 13 (12) 7587-95 (Pubitemid 23354283)
2. Guo, X. Y.; Cuillerot, J. M.; Wang, T.; Wu, Y.; Arlinghaus, R.; Claxton, D.; Bachier, C.; Greenberger, J.; Colombowala, I.; Deisseroth, A. B. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells Oncogene 1998, 17 (7) 825-33 (Pubitemid 28430205)
3. Taylor, C. M.; Keating, A. E. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain Biochemistry 2005, 44 (49) 16246-56 (Pubitemid 41785823)
4. Zhao, X.; Ghaffari, S.; Lodish, H.; Malashkevich, V. N.; Kim, P. S. Structure of the Bcr-Abl oncoprotein oligomerization domain Nat. Struct. Biol. 2002, 9 (2) 117-20 (Pubitemid 34132413)
5. Dixon, A. S.; Pendley, S. S.; Bruno, B. J.; Woessner, D. W.; Shimpi, A. A.; Cheatham, T. E., 3rd; Lim, C. S. Disruption of BCR-ABL coiled coil oligomerization by design J. Biol. Chem. 2011, 286 (31) 27751-60
6. Okimoto, R. A.; Van Etten, R. A. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol 18, (2), 89-97.
7. Goldman, J. M. Chronic myeloid leukemia: a historical perspective Semin. Hematol. 2011, 47 (4) 302-11
8. Wei, G.; Rafiyath, S.; Liu, D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib J. Hematol. Oncol. 2010, 3, 47
9. Jabbour, E.; Cortes, J. E.; Kantarjian, H. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure Clin. Lymphoma Myeloma 2009, 9 (Suppl. 3) S272-9
10. Quintas-Cardama, A.; Kantarjian, H. M.; Cortes, J. E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia Cancer Control 2009, 16 (2) 122-31
11. Deininger, M. Resistance and relapse with imatinib in CML: causes and consequences J. Natl. Compr. Cancer Network 2008, 6 (Suppl 2) S11-S21
12. Hochhaus, A.; Erben, P.; Ernst, T.; Mueller, M. C. Resistance to targeted therapy in chronic myelogenous leukemia Semin. Hematol. 2007, 44 (1 Suppl. 1) S15-24 (Pubitemid 46209243)
13. Thomas, X. Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia? Bull. Cancer 2011, 98 (7) 761-7
14. Zhou, T.; Commodore, L.; Huang, W. S.; Wang, Y.; Thomas, M.; Keats, J.; Xu, Q.; Rivera, V. M.; Shakespeare, W. C.; Clackson, T.; Dalgarno, D. C.; Zhu, X. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance Chem. Biol. Drug Des. 2011, 77 (1) 1-11
15. T315I and exhibits a narrow resistance profile Cancer Res. 2011, 71 (9) 3189-95
16. Fausel, C. Targeted chronic myeloid leukemia therapy: seeking a cure J. Managed Care Pharm. 2007, 13 (8 Suppl. A) 8-12
17. Radich, J. P. Chronic myeloid leukemia 2010: where are we now and where can we go? Hematology 2010, 2010 (1) 122-8
18. Pavlovsky, C.; Kantarjian, H.; Cortes, J. E. First-line therapy for chronic myeloid leukemia: Past, present, and future Am. J. Hematol. 2009, 84 (5) 287-93
19. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 1973, 243 (5405) 290-3
20. Groffen, J.; Stephenson, J. R.; Heisterkamp, N.; Bartram, C.; de Klein, A.; Grosveld, G. The human c-abl oncogene in the Philadelphia translocation J. Cell. Physiol. Suppl. 1984, 3, 179-91 (Pubitemid 14099986)
21. Groffen, J.; Stephenson, J. R.; Heisterkamp, N.; de Klein, A.; Bartram, C. R.; Grosveld, G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 Cell 1984, 36 (1) 93-9 (Pubitemid 14155374)
22. Kurzrock, R.; Kantarjian, H. M.; Druker, B. J.; Talpaz, M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics Ann. Intern. Med. 2003, 138 (10) 819-30 (Pubitemid 38124644)
23. Ren, R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model Oncogene 2002, 21 (56) 8629-42 (Pubitemid 36084195)
24. Sattler, M.; Griffin, J. D. Molecular mechanisms of transformation by the BCR-ABL oncogene Semin. Hematol. 2003, 40 (2 Suppl. 2) 4-10
25. Hazlehurst, L. A.; Bewry, N. N.; Nair, R. R.; Pinilla-Ibarz, J. Signaling networks associated with BCR-ABL-dependent transformation Cancer Control 2009, 16 (2) 100-7
26. Beissert, T.; Hundertmark, A.; Kaburova, V.; Travaglini, L.; Mian, A. A.; Nervi, C.; Ruthardt, M. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL Int. J. Cancer 2008, 122 (12) 2744-52 (Pubitemid 351631376)
27. McWhirter, J. R.; Wang, J. Y. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein Oncogene 1997, 15 (14) 1625-34 (Pubitemid 27466701)
28. Beissert, T.; Puccetti, E.; Bianchini, A.; Guller, S.; Boehrer, S.; Hoelzer, D.; Ottmann, O. G.; Nervi, C.; Ruthardt, M. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571 Blood 2003, 102 (8) 2985-93 (Pubitemid 37248874)
29. Mian, A. A.; Oancea, C.; Zhao, Z.; Ottmann, O. G.; Ruthardt, M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL Leukemia 2009, 23 (12) 2242-7
30. Srinivasan, J.; Cheatham, T. E., III; Cieplak, P.; Kollman, P. A.; Case, D. A. Continuum solvent studies of the stability of DNA, RNA and phosphoramidate helices J. Am. Chem. Soc. 1998, 120, 9401-9409 (Pubitemid 28452628)
31. Case, D. A.; Cheatham, T. E., III; Darden, T. A.; Gohlker, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A. V.; Simmerling, C.; Wang, B.; Woods, R. The AMBER biomolecular simulation programs J. Comput. Chem. 2005, 26, 1668-1688 (Pubitemid 43076180)
32. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
33. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725 (Pubitemid 44583220)
34. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
35. Joung, I. S.; Cheatham, T. E., III. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations J. Phys. Chem. B 2008, 112, 9020-41
36. Berendsen, H. J. C.; Postma, J. P. M; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath J. Comput. Phys. 1984, 81, 3684-90
37. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A Smooth Particle Mesh Ewald Method J. Chem. Phys. 1995, 103 (19) 8577-93
38. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-41
39. Dixon, A. S.; Kakar, M.; Schneider, K. M.; Constance, J. E.; Paullin, B. C.; Lim, C. S. Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis J. Controlled Release 2009, 140 (3) 245-9
40. Bolte, S.; Cordelieres, F. P. A guided tour into subcellular colocalization analysis in light microscopy J. Microsc. 2006, 224 (Part 3) 213-32 (Pubitemid 46010930)
41. Costes, S. V.; Daelemans, D.; Cho, E. H.; Dobbin, Z.; Pavlakis, G.; Lockett, S. Automatic and quantitative measurement of protein-protein colocalization in live cells Biophys. J. 2004, 86 (6) 3993-4003 (Pubitemid 38780275)
42. Barrett, K. L.; Willingham, J. M.; Garvin, A. J.; Willingham, M. C. Advances in cytochemical methods for detection of apoptosis J. Histochem. Cytochem. 2001, 49 (7) 821-32 (Pubitemid 32565976)
43. Willingham, M. C. Cytochemical methods for the detection of apoptosis J. Histochem. Cytochem. 1999, 47 (9) 1101-10